Stryker Corporation is a medical technology company that develops and sells products and services across three main business segments: MedSurg, Neurotechnology, and Orthopaedics. The company provides solutions designed to improve patient and healthcare outcomes, serving customers in the medical and surgical, neurotechnology, and orthopaedic fields. Founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon, the company operates globally, impacting patients in the Americas, Asia Pacific, and the Middle East & Africa regions.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage stryker.com
Sector Healthcare IR page stryker.com
Tags
medical technology, medsurg, neurotechnology, orthopaedics, spine, patient care, surgical instruments
Press page —

Metrics

Valuation  
Market cap $ 125.224B
Market cap (USD) $ 125.224B
P/E 34.67
PEG 3.08
P/BV 5.34
P/S 4.76
P/OCF 22.99
P/FCF 27.38
Dividend yield 1.1%
Turnover / mcap —
Returns  
ROE 15.1%
ROI 8.5%
ROIC 9.2%
Profit margin 12.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 11.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 63.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score 36.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 25.116B 22.595B 20.498B 18.449B 17.108B 14.351B 14.884B 13.601B 12.444B 11.325B 9.946B 9.675B 9.021B 8.657B 8.307B 7.32B 6.723B 6.718B 6.001B 5.406B 4.872B 4.262B 3.625B 3.012B 2.602B 2.289B
Net profit 3.246B 2.993B 3.165B 2.358B 1.994B 1.599B 2.083B 3.553B 1.02B 1.647B 1.439B 515M 1.006B 1.298B 1.345B 1.273B 1.107B 1.148B 1.017B 777.7M 675.2M 465.7M 453.5M 345.6M 267M 113.9M
Free cash flow 4.283B 3.487B 3.136B 2.036B 2.738B 2.79B 1.542B 2.038B 961M 1.322B 629M 1.549B 1.691B 1.447B 1.208B 1.365B 1.329B — 840.6M 649.8M 592.1M 405.5M 504M 364.9M 306.4M 251.1M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 351.47 360.05 299.46 244.49 267.42 245.04 209.94 156.75 154.84 119.81 92.94 94.33 75.14 54.82 49.7 53.7 50.38 39.95 72.62 54.88 45.96 — — — — —
Price performance 12m -0.02 0.2 0.22 -0.09 0.09 0.17 0.34 0.01 0.29 0.29 -0.01 0.26 0.37 0.1 -0.07 0.07 0.26 -0.45 0.32 0.19 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.97B 2.2B 2.33B 2.89B 2.7B 3.02B 3.57B 3.77B 3.99B 4.04B
↳ YoY growth +18.4% +11.7% +6.1% +24.1% -6.6% +11.9% +18.0% +5.6% +5.9% +1.3%
↳ 5y CAGR +6.8% +9.0% +9.0% +13.0% +10.2% +9.0% +10.2% +10.1% +6.6% +8.4%
Borrowings, current (USD) 200M 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Borrowings, non-current (USD) 6.69B 6.59B 8.49B 10.2B 13.2B 12.5B 11.9B 10.9B 12.2B 14.9B
Lease liabilities (USD) — — — 387M 434M 422M 478M 499M 523M 501M
Cash and deposits (USD) 3.32B 2.54B 3.62B 4.34B 2.94B 2.94B 1.84B 2.97B 3.65B 4.01B
Intangible assets (USD) 3.51B 3.48B 4.16B 4.23B 5.55B 4.84B 4.89B 4.59B 4.4B 5.68B
Right-of-use assets (USD) — — — 384M 423M 419M 473M 494M 516M 519M
Net debt (borrowings + leases - cash) (USD) 3.57B 4.05B 4.87B 6.28B 10.3B 9.95B 10.5B 8.43B 9.06B 11.3B
Cash flow detail
Operating cash flow (USD) 1.81B 1.56B 2.61B 2.19B 3.28B 3.26B 2.62B 3.71B 4.24B 5.04B
Purchases of property, plant and equipment (USD) -490M -598M -572M -649M -487M -525M -588M -575M -755M -761M
Change in receivables (cash effect) (USD) -192M -162M -60M -563M 354M -377M -579M -175M -321M 127M
Change in inventories (cash effect) (USD) -299M -320M -385M -400M 27M -189M -762M -797M -206M -297M
Dividends paid (cash effect) (USD) -568M -636M -703M -778M -863M -950M -1.05B -1.14B -1.22B -1.28B
Share buybacks (cash effect) (USD) -13M -230M -300M -307M 0.00 0.00 — — — —
Interest paid (cash effect) (USD) -180M -264M -248M -286M -304M -325M -324M -356M -396M -582M
Income taxes paid (cash effect) (USD) -510M -312M -539M -457M -323M -622M -505M -693M -989M -1B
Share-based compensation (USD) 97M 113M 119M 127M 142M 171M 168M 205M 229M 243M
Operating cash flow before change in receivables (USD) 2B 1.72B 2.67B 2.75B 2.92B 3.64B 3.2B 3.89B 4.56B 4.92B
Free cash flow (OCF - PPE - intangibles) (USD) 1.32B 961M 2.04B 1.54B 2.79B 2.74B 2.04B 3.14B 3.49B 4.28B
Income detail
Research and development expense (USD) 715M 787M 862M 971M 984M 1.24B 1.45B 1.39B 1.47B 1.62B
↳ 5y CAGR +9.1% +10.8% +10.0% +9.6% +9.5% +11.6% +13.1% +10.0% +8.6% +10.5%
Total comprehensive income (USD) 1.53B 1.23B 3.48B 2.11B 1.05B 2.62B 2.67B 2.97B 3.12B 2.85B
Comprehensive income to owners (USD) 1.53B 1.23B 3.48B 2.11B 1.05B 2.62B 2.67B 2.97B 3.12B 2.85B
Reported Feb 9, 2017 Feb 8, 2018 Feb 7, 2019 Feb 6, 2020 Apr 28, 2021 Feb 11, 2022 Feb 10, 2023 Feb 14, 2024 Feb 12, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PORTAGE, Mich. – Nov. 9, 2026 – Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the company’s board, effective Jan. 1, 2027.

Jim serves as Chairman, CEO and President of Quest Diagnostics. He brings extensive leadership experience across healthcare, medical technology and global operations.

Before joining Quest, Jim served as CEO of InSightec, Inc., a global medical device company. Prior to that, he spent two decades in senior management roles across General Electric’s healthcare and aviation businesses, including five years leading GE’s MRI business. Before GE, Jim led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc.

Jim holds a master’s degree in management from the MIT Sloan School of Management, a master’s degree in science from MIT and a bachelor’s degree in aeronautical engineering from the University of Michigan.

“We are pleased to have Jim as a nominee for our board,” said Kevin Lobo, Chair and CEO, Stryker.

STRYKER REPORTS THIRD QUARTER 2026 OPERATING RESULTS Bull 4 Bear 3 Results

Portage, Michigan - October 29, 2026 - Stryker (NYSE:SYK) reported operating results for the third quarter of 2026:

Third Quarter Results

•Reported net sales increased 7.7% to $6.5 billion

•Organic net sales increased 7.7%

•Reported operating income margin of 15.9%

•Adjusted operating income margin(1) increased 60 bps to 26.2%

•Reported EPS decreased 11.7% to $1.96

•Adjusted EPS(1) increased 10.3% to $3.52

Third Quarter Net Sales Growth Overview

Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Organic

MedSurg and Neurotechnology 9.2 % — % 9.2 % 0.1 % 9.1 %

Orthopaedics 5.7 (0.2) 5.9 — 5.9

Total 7.7 % — % 7.7 % — % 7.7 %

“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter,” said Kevin A. Lobo, Chair and CEO. “While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.”

Sales Analysis

Consolidated net sales of $6.5 billion increased 7.7% in the quarter on both a reported and constant currency basis.

27-Oct-2026

false

Meeting the colonoscopy boom feature story_desktop

Colonoscopy and colorectal cancer screening procedures are on the rise across the country.1 As the U.S. Preventive Services Task Force expands screening eligibility from age 50 to 45 in response to rising colorectal cancer rates among younger adults, gastrointestinal (GI) teams are working to keep pace with growing demand.2

Why it matters

Behind every colonoscopy is a team working to deliver safe, efficient care. As demand for screening grows, technologies like the Neptune S Waste Management System can help protect healthcare professionals from exposure to biohazardous waste while supporting procedural workflows that help contribute to safer environments for both caregivers and patients.

Growing demand for colorectal cancer screening

Colonoscopy remains one of the most important tools in colorectal cancer screening. In recent years, the number of people eligible for colon cancer screening has increased following updated recommendations from the U.S. Preventive Services Task Force, which lowered the recommended starting age for average-risk adults from 50 to 45.2

For gastroenterologists and their teams, the challenge isn't simply how long a colonoscopy takes. It's everything surrounding the procedure. Preparing procedure rooms, managing fluid waste, processing specimens and turning rooms over between patients all contribute to the workflow surrounding a colonoscopy.

As procedure volumes grow, healthcare organizations are increasingly evaluating technologies and workflows that can support caregiver safety, reduce unnecessary manual tasks and help teams work more efficiently. Among them, the systems used to manage fluid waste during a colonoscopy procedure can play an important role.

Supporting healthcare teams through every colonoscopy procedure

The impact of higher procedure volumes can be felt among healthcare professionals working in the gastroenterology (GI) suite, where routine workflow challenges become more pronounced as schedules fill.

At one facility, certified gastroenterology nurse Connie Hall, RN, reported that five procedure rooms were handling approximately 500 to 600 colonoscopies each month, with at least 1,000 additional patients waiting to be scheduled. “We’re on a trajectory to break any record we would have thought about setting,” she said. 3

Higher procedure volumes can magnify inefficiencies that may once have seemed routine. For Hall's team, one of those challenges was fluid waste management.

Why fluid waste management matters during colonoscopy screening

During a colonoscopy, fluid and other waste must be collected and managed safely. Traditionally, a canister-based system is used by care teams, and as it gets filled, it may require staff to change canisters during a procedure. Those additional steps can add work and stress for the clinical team. They can also create opportunities for staff exposure to biohazardous fluids when handling waste.

Healthcare organizations may benefit from examining how waste management processes affect both workflow and caregiver safety. Technologies such as Stryker's Neptune S Waste Management System are designed to help reduce manual handling of biohazardous fluid, supporting a safer environment for healthcare professionals while helping streamline workflow throughout the day.

Neptune S is described as a ’closed waste management system’ that offers an alternative to traditional canister handling. The system provides consistent suction while helping protect staff from unintentional exposure to biohazardous fluid and spills. Instead of requiring staff to repeatedly interact with individual waste canisters, the system can help streamline fluid collection and management throughout a colonoscopy procedure.

That distinction becomes increasingly important at scale. In a GI department completing hundreds of procedures each month, changing waste canisters two or three times during some procedures, reducing repetitive manual tasks may help staff maintain workflow while limiting unnecessary interactions with biohazardous waste.

Stryker's Neptune S Waste Management System

Addressing polyp retrieval

Fluid isn't the only thing passing through a suction system during a colonoscopy. Polyps, or clusters of cells that form in the colon, may be removed during the procedure and collected for further testing. When a removed polyp cannot be easily located, retrieval can add time and complexity to an already busy workflow, sometimes requiring healthcare professionals to manually search through collected waste.

Colonoscopy procedure showing a polyp in the large intestine

That’s why Neptune S incorporates an illuminated manifold port and backup basket designed to help prevent the loss of polyps 2 mm or larger. By supporting specimen collection alongside suction and waste management, the system helps simplify several interconnected steps within the colonoscopy workflow.

“It was labor intensive to change out those canisters. The way you had to go through them to find a missing polyp, now that’s a day you don’t want to repeat very often,” Hall recalls.

By helping simplify specimen collection and reducing the need for manual searches through collected waste, Neptune S supports caregiver safety and efficiency while helping to facilitate important tissues, such as polyps, 2mm or larger, are successfully recovered for evaluation.

Designing the GI suite around the people inside

As demand for colonoscopy screening grows, facilities have an opportunity to examine more than scheduling and procedure volume alone.

  • How often are staff changing waste canisters?

  • Where are unnecessary exposures occurring?

  • What happens when a polyp is difficult to retrieve?

  • Are existing processes adding steps that could be reduced or eliminated?

Those questions can help uncover opportunities to improve both safety and efficiency. The result is a GI environment designed not only around getting more procedures done, but around helping the people who perform them do their jobs safely and efficiently.

Our philosophy extends beyond colonoscopy

Healthcare workers deserve the same protection and advocacy as the patients they care for. Through our Journey to Zero* Harm initiative, we are committed to helping reduce preventable sources of harm in healthcare environments, supporting safer conditions for caregivers and patients alike.

Learn more

Our goal is Zero*

ST-zero-splashes-and-spills

Zero splashes
and spills

ST-zero-surgical-smoke

Zero surgical
smoke

ST-zero-lost-polyps

Zero lost
polyps**

ST-zero-maternal-harm

Zero maternal
harm

ST-zero-retained-sponges

Zero retained sponges

ST-zero-hypoxic-injuries

Zero hypoxic injuries***

*Zero harm and zero doubt messages are not guaranteed and are aspirational in nature

** Lost polyps: 2mm or larger

*** Hypoxic injuries: POM mask can provide consistent and reliable capnography waverforms to identify hypoxic events

References

  1. Shaukat A, Church T. Colorectal cancer screening in the USA in the wake of COVID-19. Lancet Gastroenterol Hepatol. 2020Aug;5(8):726-727. doi: 10.1016/S2468-1253(20)30191-6. Epub 2020 Jun 19. PMID:32569576; PMCID: PMC7304951.
  2. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238
  3. This is a paid interview with a Stryker nurse consultant, conducted March 22, 2023, on behalf of Stryker.

ST-NEPS-ARTI-3901150_REV-0

Last Updated October/2026

© Stryker 1998-2026 |

Prompts

Stryker Corporation (ticker SYK), listed in United States.

Company History

Date Change Detail
Nov 3, 2017 Acquired Acquired Entellus Medical Inc (CIK 1374128). Its filings from before the deal are on its own company page, not shown here.
Nov 13, 2013 Acquired Acquired Patient Safety Technologies, Inc (CIK 812301). Its filings from before the deal are on its own company page, not shown here.
Nov 6, 2013 Acquired Acquired Mako Surgical Corp. (CIK 1411861). Its filings from before the deal are on its own company page, not shown here.
May 4, 2011 Acquired Acquired Orthovita Inc (CIK 913756). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Stryker Corporation

ETF Weight in ETF Shares Market value As of
JGRW 3.97% 10,769 $ 3.487M Aug 31, 2026
CWS 3.71% 12,938 $ 4.108M Nov 17, 2026
SEMG 3.66% 7,096 $ 2.25M Nov 18, 2026
BEEX 2.40% 14,442 $ 4.487M Nov 17, 2026
KAT 2.24% 46,320 $ 14.583M Jun 30, 2026
TMED 2.22% 1,624 $ 511.3K Jun 30, 2026
JDOC 2.16% 671 $ 213.069K Nov 17, 2026
GGRW 2.14% 595 $ 187.33K Jun 30, 2026
FGSI 2.12% 136 $ 43.355K Nov 11, 2026
GKAT 2.11% 10,737 $ 3.38M Jun 30, 2026
CVRD 1.97% 2,000 $ 629.68K Jun 30, 2026
PRCS 1.94% 12,567 $ 3.461M Sep 30, 2026
FRIZ 1.88% 314 $ 98.86K Jun 30, 2026
RUNN 1.80% 23,157 $ 7.498M Aug 31, 2026
KNO 1.76% 2,540 $ 799.694K Jun 30, 2026
ESLV 1.48% 648 $ 211.054K Jul 31, 2026
HRTS 1.33% 2,284 $ 739.559K Aug 31, 2026
ESLG 1.31% 937 $ 305.181K Jul 31, 2026
THMZ 1.28% 2,207 $ 694.852K Jun 30, 2026
QIDX 1.26% 1,508 $ 491.156K Jul 31, 2026
BRIF 1.26% 6,158 $ 1.939M Jun 30, 2026
SAWG 1.11% 98 $ 31.919K Jul 31, 2026
PSET 1.10% 1,004 $ 316.099K Jun 30, 2026
LRGC 0.98% 40,465 $ 13.103M Aug 31, 2026
PY 0.98% 6,838 $ 2.153M Jun 30, 2026
QLTY 0.93% 148,998 $ 48.246M Aug 31, 2026
ESUM 0.92% 5,156 $ 1.679M Jul 31, 2026
ZECP 0.78% 9,038 $ 2.927M Aug 31, 2026
JAVA 0.77% 180,557 $ 57.334M Nov 17, 2026
GDMA 0.75% 4,415 $ 1.4M Nov 18, 2026
PRAY 0.73% 1,810 $ 569.86K Jun 30, 2026
NPFE 0.71% 14,071 $ 4.583M Jul 31, 2026
LCDS 0.70% 349 $ 110.821K Nov 17, 2026
JGLO 0.68% 124,207 $ 39.441M Nov 17, 2026
JOYT 0.68% 2,527 $ 802.424K Nov 17, 2026
HELO 0.60% 90,149 $ 28.626M Nov 17, 2026
BAMG 0.55% 2,160 $ 699.408K Aug 31, 2026
JDIV 0.53% 204 $ 64.778K Nov 17, 2026
JEPI 0.52% 753,389 $ 239.231M Nov 17, 2026
ENHU 0.51% 153 $ 47.54K Nov 16, 2026
TCAL 0.51% 5,414 $ 1.682M Nov 17, 2026
CAPE 0.50% 3,765 $ 1.185M Jun 30, 2026
PAPI 0.48% 6,152 $ 1.937M Jun 30, 2026
TGRT 0.45% 23,448 $ 7.286M Nov 17, 2026
NBCR 0.43% 11,255 $ 3.644M Aug 31, 2026
JUSA 0.42% 11,625 $ 3.691M Nov 17, 2026
ACIO 0.40% 28,561 $ 9.302M Jul 31, 2026
ADME 0.40% 3,557 $ 1.159M Jul 31, 2026
MPLY 0.30% 146 $ 47.552K Jul 31, 2026
CDX 0.28% 2,156.2192 $ 684.686K Nov 17, 2026
GPT 0.27% 202 $ 63.598K Jun 30, 2026
DFLV 0.27% 65,399 $ 20.43M Nov 12, 2026
XMAG 0.26% 1,766 $ 551.681K Nov 13, 2026
STOX 0.25% 1,743 $ 564.383K Aug 31, 2026
MODL 0.24% 7,897 $ 2.486M Jun 30, 2026
VFQY 0.24% 3,832 $ 1.241M Aug 31, 2026
TVAL 0.23% 8,465 $ 2.63M Nov 17, 2026
SFTY 0.23% 5,541 $ 1.794M Aug 31, 2026
ACVF 0.22% 1,032 $ 336.122K Jul 31, 2026
PINK 0.20% 2,148 $ 682.076K Nov 17, 2026
DFUV 0.20% 100,892 $ 31.518M Nov 12, 2026
TACU 0.20% 117 $ 36.354K Nov 17, 2026
DFVX 0.18% 3,340 $ 1.043M Nov 12, 2026
FTLS short -0.18% -14,688 $ 0.00 Nov 16, 2026
GEW 0.17% 766 $ 248.031K Aug 31, 2026
NTSX 0.17% 7,327 $ 2.307M Jun 30, 2026
VOXP 0.17% 30 $ 9,771.00 Jul 31, 2026
GDE 0.16% 2,383 $ 771.615K Aug 31, 2026
DFUS 0.15% 104,755 $ 32.724M Nov 12, 2026
NTSD 0.15% 170 $ 53.523K Jun 30, 2026
HEQQ 0.15% 135 $ 42.868K Nov 17, 2026
HCMT 0.14% 2,402 $ 782.331K Jul 31, 2026
DFSU 0.13% 9,755 $ 3.047M Nov 12, 2026
DFAU 0.12% 50,423 $ 15.752M Nov 12, 2026
MSLC 0.11% 13,289 $ 4.303M Aug 31, 2026
APUE 0.10% 7,939 $ 2.571M Aug 31, 2026
AAUS 0.10% 1,562 $ 500K Nov 18, 2026
DCOR 0.10% 142,704 $ 44.579M Nov 12, 2026
AVSU 0.08% 1,207 $ 375.039K Nov 16, 2026
DFAC 0.07% 203,590 $ 63.599M Nov 12, 2026
AVUS 0.07% 32,671 $ 10.152M Nov 16, 2026
AVLC 0.07% 3,389 $ 1.053M Nov 16, 2026
CSHP 0.06% 717 $ 222.786K Nov 16, 2026
INRO 0.06% 1,097 $ 340.86K Nov 16, 2026
GSPY 0.06% 1,365 $ 424.133K Nov 17, 2026
DXUV 0.04% 8,695 $ 2.716M Nov 12, 2026
DYNF 0.03% 40,243 $ 12.504M Nov 16, 2026
JFLI 0.03% 51 $ 16.195K Nov 17, 2026
IALT 0.02% 5,814 $ 1.807M Nov 16, 2026
EBI 0.02% 396 $ 128.225K Aug 31, 2026
FELV 0.00% 200 $ 62.968K Jun 30, 2026
CORO 0.00% 220 $ 68.405K Nov 16, 2026